29.07.2015 • News

HCS to Acquire Shu-Chem of Texas

“The US market is a strategic target in our international growth strategy,”...
“The US market is a strategic target in our international growth strategy,” said Uwe Nickel, CEO of HCS

Frankfurt, Germany-based HCS Group, driving forward its expansion into the US market, has announced it will acquire Shu-Chem Holdings, based at Manvel near Houston, Texas. Since 1983, Shu-Chem has produced alcohols and esters mainly for the pharmaceutical aand printing industries.

“The US market is a strategic target in our international growth strategy,” said Uwe Nickel, CEO of HCS, which owns the brands Haltermann and Carless.

“With the acquisition of Shu-Chem, we will not only gain a production basis in North America but at the same time will extend our offerings for the US market,” he added.

Nickel said the two companies complement each other “ideally,” as both have a similar business model.

For the US company, being acquired by HCS, a leading international producers of high-end hydrocarbons and other specialties, also has advantages, said Sue S. Schwartz, Integration into the German firm’s structure “will set the stage for further growth and innovation,” Schwartz said.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read